Financial Analysis: enVVeno Medical (NASDAQ:NVNO) and ICU Medical (NASDAQ:ICUI)

enVVeno Medical (NASDAQ:NVNO) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Profitability

This table compares enVVeno Medical and ICU Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-48.72%	-45.96%
ICU Medical	-4.74%	5.04%	2.42%

Valuation & Earnings

This table compares enVVeno Medical and ICU Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$23.52 million	($1.29)	-2.64
ICU Medical	$2.26 billion	1.86	-$29.66 million	($4.57)	-37.63

enVVeno Medical has higher earnings, but lower revenue than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

enVVeno Medical has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for enVVeno Medical and ICU Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	0	0	0	0	0.00
ICU Medical	0	2	3	0	2.60

ICU Medical has a consensus target price of $173.00, suggesting a potential upside of 0.60%. Given ICU Medical’s stronger consensus rating and higher probable upside, analysts plainly believe ICU Medical is more favorable than enVVeno Medical.

Institutional & Insider Ownership

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 96.1% of ICU Medical shares are owned by institutional investors. 17.0% of enVVeno Medical shares are owned by company insiders. Comparatively, 6.7% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

ICU Medical beats enVVeno Medical on 7 of the 13 factors compared between the two stocks.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

About ICU Medical

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.